Compare SRCE & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRCE | GHRS |
|---|---|---|
| Founded | 1863 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1995 | 2021 |
| Metric | SRCE | GHRS |
|---|---|---|
| Price | $87.43 | $20.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $95.00 | $42.89 |
| AVG Volume (30 Days) | 98.9K | ★ 295.9K |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 19.59 | N/A |
| EPS | ★ 5.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.20 | N/A |
| Revenue Next Year | $3.21 | N/A |
| P/E Ratio | $15.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.91 | $12.04 |
| 52 Week High | $91.46 | $31.44 |
| Indicator | SRCE | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 47.43 |
| Support Level | $82.85 | $19.75 |
| Resistance Level | $87.66 | $22.88 |
| Average True Range (ATR) | 1.71 | 1.12 |
| MACD | 0.27 | 0.53 |
| Stochastic Oscillator | 63.55 | 70.15 |
1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.